Domestic researchers have laid the groundwork for precise brain analysis of patients with Alzheimer's disease and classify them into three subtypes. The study is expected to be the cornerstone of the drug for precise dementia because Alzheimer's Dementia treatment is administered through precision medicine.
Prof. Zhang-Yang Roh, a professor of neurology at Gilhon University Hospital, Na-Deok-Rul at the Samsung & Evans Medical Center, McGill University, Canada, analyzed images of the amyloid brain and tau alveoli (tau protein) linked to the brain protein. ), Parietal (P) dominant subtype and broadly atrophic subtype (D).
In this study, 83 patients with Alzheimer's Dementia and 60 healthy subjects performed not only magnetic resonance imaging (MRI) but also the latest imaging techniques, such as Tau positron emission tomography (PET) and emission tomography. amyloid positron (PET). It's worth it because MRI is a device that mainly monitors atrophy of the brain and tells the progress of the disease, while Tau PET and amyloid PET tell which diseases are in the brain.
The main advantage of this study is the cluster analysis of the similarity between the distribution of cerebral cortex atrophy, brain-accumulated amyloid and protein tau in combination with brain imaging data obtained by MRI in patients with Alzheimer's Dementia and Alzheimer's disease FIVE. It was realized using this method.
The study found three different subtypes in Alzheimer's Dementia. A total of 83 dementia patients with Alzheimer's disease were classified into 44 medial temporal dominant subtypes, 20 extensive atrophic subtypes, and 19 parietal dominant subtypes.
Three subtypes of Alzheimer's Dementia showed different clinical and pathological features. Patients with medial temporal dominant subtype were characterized by aging (9.37 34 34.34) 72.37), female dominance (84.1%), memory-oriented cognitive decline, and parietal dominant subtype were younger onset (6.09 56 56.12) and the thinnest cortical thickness. There was a marked decrease in cognitive functions except memory, such as concentration of attention, spatiotemporal ability and frontal / executive function. Huge atrophic subtypes showed clinical features in the middle of both groups. The distribution of atrophy of the cerebral cortex and the distribution of proteins in tau are different in three subtypes, whereas the distribution of amyloid is similar in three groups.
Professor Roach said: "Although the brains of Alzheimer's patients were diagnosed with MRI, they were classified into three types according to the type of brain atrophy. This allows us to classify the subspecies more accurately and accurately. "
The research team was able to do a deeper examination of the brain of patients with dementia with Alzheimer's disease to develop imaging techniques. Tau PET scanners (radioactive materials used in the body) are used to early diagnose Alzheimer's disease and to assess the progression of Alzheimer's disease through observation of tau pathology.
Professor Roch said: "The results of this study are used to detect the pathology of Tau using Tau PET for the differential diagnosis of Alzheimer's and non-Alzheimer's dementia." This study determines the clinical and pathological features of dementia in Alzheimer's as well as the presence of the disease. It can be used to classify subtypes. "
Team research is <
By Kim Jong-kyung firstname.lastname@example.org
Protected Rights "Honest Knowledge of Health" Comedy.com (http://kormedi.com) / All rights reserved.